Chimerix to Present at Jefferies London Healthcare Conference

Rhea-AI Summary

Chimerix (NASDAQ:CMRX) announced that CEO Mike Sherman will present at the Jefferies London Healthcare Conference on November 18, 2021, at 3:00 a.m. ET. This pre-recorded presentation will be accessible via an audio webcast on Chimerix's Investor Relations website, where it will be archived for 90 days. Chimerix focuses on developing medicines for patients with life-threatening diseases, having recently received FDA approval for TEMBEXA to treat smallpox and advancing clinical-stage programs for ONC201 and dociparstat sodium in oncology.

DURHAM, N.C., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX),a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer of Chimerix, will participate in a pre-recorded presentation at the Jefferies London Healthcare Conference that will be made available on Thursday, November 18, 2021 at 3:00 a.m. ET.

An audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.

About Chimerix

Chimerix is a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. In June 2021, the U.S. Food and Drug Administration granted approval of TEMBEXA for the treatment of smallpox as a medical countermeasure. The Company has two other advanced clinical-stage development programs, ONC201 and dociparstat sodium (DSTAT). ONC201 is in development for recurrent H3 K27M mutant glioma. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia.

CONTACT:

Investor Relations:
Michelle LaSpaluto
919 972-7115
ir@chimerix.com

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com

FAQ

What is the date of the Chimerix presentation at the Jefferies London Healthcare Conference?

The presentation is scheduled for November 18, 2021, at 3:00 a.m. ET.

Where can I access the Chimerix presentation after it airs?

The presentation will be available on Chimerix's Investor Relations website and archived for about 90 days.

What is the focus of Chimerix as a biopharmaceutical company?

Chimerix focuses on developing medicines that improve and extend the lives of patients facing deadly diseases.

What recent FDA approval did Chimerix receive?

Chimerix received FDA approval for TEMBEXA for the treatment of smallpox.

What are the clinical-stage programs being developed by Chimerix?

Chimerix is advancing ONC201 for recurrent H3 K27M mutant glioma and dociparstat sodium in acute myeloid leukemia.